Use of adenosine receptor agonists in therapy
AssigneeCambridge Biotechnology Ltd
InventorPeter Richardson
Life of this patent
Estimating the term…
Abstract
Use of compounds of formula: (I) wherein R is C1-4 alkoxy and X is H or OH; for the prevention, treatment, or amelioration of cancer, inflammation, auto-immune disease, ischemia-reperfusion injury, epilepsy, sepsis, septic shock, neurode-generation (including Alzheimer's Disease), muscle fatigue or muscle cramp is described. The compounds are effective at very low doses, and so can be administered at doses at which serious side effects are not observed.
Claims14
1-11. (canceled)
A pharmaceutical composition in unit dose form comprising up to 500 mg of 2-methoxyadenosine and a physiologically acceptable carrier, excipient, or diluent.
A method of prevention, treatment, or amelioration of cancer, inflammation, auto-immune disease, ischemia-reperfusion injury, epilepsy, sepsis, septic shock, neurodegeneration (including Alzheimer's Disease), muscle fatigue or muscle cramp, which comprises administering a compound of formula (I):
- wherein R is C1-4 alkoxy, and X is H or OH;
- to a subject in need of such prevention, treatment, or amelioration at a dosage which gives rise to a peak plasma concentration in the subject that is less than the EC50 value of the compound at adenosine receptors at pH 7.4.
Use of a compound of formula (I):
- wherein R is C1-4 alkoxy, and X is H or OH;
- for discovery of drugs for the prevention, treatment, or amelioration of cancer, inflammation, ischemia-reperfusion injury, epilepsy, sepsis, septic shock, neurodegeneration (including Alzheimer's Disease), muscle fatigue or muscle cramp.
Dependencies are inferred from the claim text.